TR201907568T4 - [5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu. - Google Patents

[5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu. Download PDF

Info

Publication number
TR201907568T4
TR201907568T4 TR2019/07568T TR201907568T TR201907568T4 TR 201907568 T4 TR201907568 T4 TR 201907568T4 TR 2019/07568 T TR2019/07568 T TR 2019/07568T TR 201907568 T TR201907568 T TR 201907568T TR 201907568 T4 TR201907568 T4 TR 201907568T4
Authority
TR
Turkey
Prior art keywords
methylindol
fluorobenzene
pyridin
sulfonyl
fluoro
Prior art date
Application number
TR2019/07568T
Other languages
English (en)
Turkish (tr)
Inventor
Hilfiker Rolf
Grosse-Sender Katja
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of TR201907568T4 publication Critical patent/TR201907568T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/07568T 2014-05-02 2015-05-01 [5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu. TR201907568T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1407820.8A GB201407820D0 (en) 2014-05-02 2014-05-02 Polymorphic form

Publications (1)

Publication Number Publication Date
TR201907568T4 true TR201907568T4 (tr) 2019-06-21

Family

ID=50980534

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07568T TR201907568T4 (tr) 2014-05-02 2015-05-01 [5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu.

Country Status (8)

Country Link
US (1) US9951042B2 (cg-RX-API-DMAC7.html)
EP (1) EP3137453B8 (cg-RX-API-DMAC7.html)
JP (1) JP2017514841A (cg-RX-API-DMAC7.html)
GB (1) GB201407820D0 (cg-RX-API-DMAC7.html)
RU (1) RU2702343C2 (cg-RX-API-DMAC7.html)
TR (1) TR201907568T4 (cg-RX-API-DMAC7.html)
UA (1) UA121476C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015166280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CN108949699B (zh) * 2018-08-03 2020-09-04 江南大学 一种分泌美洛昔康单克隆抗体的杂交瘤细胞株及其应用
WO2020193459A1 (en) * 2019-03-25 2020-10-01 F. Hoffmann-La Roche Ag Solid forms of a compound of hbv core protein allosteric modifier

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
DK151884C (da) 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en) 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4478842A (en) 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3514696A1 (de) 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
US5214059A (en) 1989-07-03 1993-05-25 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
CA2135160A1 (en) 1992-05-08 1993-11-25 Masatoshi Inai Indole derivative
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
WO1997046677A1 (fr) 1996-06-05 1997-12-11 Bml, Inc. PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU774929B2 (en) 1998-03-31 2004-07-15 Institutes For Pharmaceutical Discovery, Llc, The Substituted indolealkanoic acids
CZ20003985A3 (cs) 1998-04-28 2001-09-12 Arzneimittelwerk Dresden Gmbh Nový hydroxyindol, způsob jeho přípravy a jeho použití jako inhibitoru fosfodiesterázy 4
EP0984012A3 (en) 1998-08-31 2001-01-10 Pfizer Products Inc. Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001014882A1 (fr) 1999-08-23 2001-03-01 Bml, Inc. Identification des proprietes d'une substance pour les recepteurs de prostaglandine d
WO2001051489A2 (en) 2000-01-14 2001-07-19 The Institutes For Pharmaceutical Discovery, Llc Methods for lowering uric acid levels
US6521659B2 (en) 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja) 2000-03-08 2001-09-11 Japan Tobacco Inc インドール酢酸化合物及びその製造方法
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
JP4484108B2 (ja) 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MXPA05006282A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados del acido 1h-indol-1-il acetico de 3-alquilo y 3-arilalquilo sustituido como inhibidores del inhibidor-1 de activador de plasminogeno (pai-1).
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
EP1675826A1 (en) 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
BRPI0416238A (pt) 2003-11-05 2007-01-02 Hoffmann La Roche compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa)
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
JP2007533725A (ja) 2004-04-20 2007-11-22 ファイザー・インク Ｃｒｔｈ２受容体アンタゴニストを用いたニューロパシー性疼痛処置方法
JP4793692B2 (ja) 2004-04-26 2011-10-12 小野薬品工業株式会社 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
US7405215B2 (en) 2004-09-21 2008-07-29 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
CA2618550C (en) 2005-08-12 2013-12-17 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
GB0614068D0 (en) 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
GB0614066D0 (en) 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
EP2492268A1 (en) 2006-07-22 2012-08-29 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
PL2327693T3 (pl) 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
RU2503672C2 (ru) * 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
WO2009090399A1 (en) 2008-01-18 2009-07-23 Argenta Discovery Limited Indoles active on crth2 receptor
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
EP2300425A4 (en) 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) * 2011-12-15 2012-01-25 Oxagen Ltd Process
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407813D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form

Also Published As

Publication number Publication date
JP2017514841A (ja) 2017-06-08
US20170121306A1 (en) 2017-05-04
EP3137453B1 (en) 2019-02-27
UA121476C2 (uk) 2020-06-10
WO2015166280A1 (en) 2015-11-05
EP3137453A1 (en) 2017-03-08
US9951042B2 (en) 2018-04-24
RU2702343C2 (ru) 2019-10-08
GB201407820D0 (en) 2014-06-18
EP3137453B8 (en) 2019-05-15
RU2016142519A3 (cg-RX-API-DMAC7.html) 2018-11-02
RU2016142519A (ru) 2018-06-05

Similar Documents

Publication Publication Date Title
CR20140464A (es) Compuestos de heterociclilo
CL2017001675A1 (es) Derivados de quinazolina utilizados para tratar el vih
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
PL3233141T4 (pl) Generowanie kwasu peroksymrówkowego poprzez mrówczan alkoholu wielowodorotlenowego
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
CO7160104A2 (es) Inhibidores de virus de hepatitis c
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CR20150061A (es) Compuesto de pirazolopirimidinas
EA201591567A1 (ru) Новые производные пиридина
EA201591451A1 (ru) Модуляторы flap
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MX2017007377A (es) Compuestos organicos.
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
AR095727A1 (es) Preparación de intermediarios de pirimidina
EA201591976A1 (ru) Производные пурина в качестве агонистов каннабиноидного рецептора cb2
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
CR20150257A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina
CU24293B1 (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
BR112016028022A2 (pt) compostos de sulfonamida e seus usos como inibidores de stat5
TR201907568T4 (tr) [5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu.
UY34595A (es) Composición farmacéutica de liberación prolongada de trimetazidina